Advantages of using thalidomide for the management of patients with refractory myeloma

Research output: Contribution to journalArticle


A group of 11 heavily pretreated patients receiving low-dose thalidomide was compared with a similar group of 10 patients with refractory myeloma treated with a conventional oral chemotherapy. This study shows that thalidomide is not only effective in controlling the neoplastic clone but moreover, thanks to its low toxicity, allows out-patient management of these subjects.

Original languageEnglish
Pages (from-to)327-328
Number of pages2
Issue number3
Publication statusPublished - 2002



  • Chemotherapy
  • Outpatients
  • Refractory myeloma
  • Thalidomide
  • Toxicity

ASJC Scopus subject areas

  • Hematology

Cite this